provided. Similarly, has the data safety monitoring committee actually been appointed, or is this something planned for the future? The primary outcomes are discussed in more detail on pp 8-9 and again, it is not clear whether these are the same for both studies, though one has to assume that they are. Please clarify whether the mean and 95% CI of the treatment groups must be within 11-13g/dL, or whether this really is each patient's mean and 95% CI. Given there are 4 measures during the evaluation period, it is highly likely that the lower and upper bounds of the 95% CI of each patient will cross the boundaries. What is the reason for such a stringent measure of Hb being within target? Is the intention to report as the primary outcome the actual mean Hb between groups, or the proportion meeting the primary efficacy criteria? The sample size calculation appears to be based on the former. On p 8 it is stated that "The primary objective will be achieved if two conditions are met". This implies an outcome where the proportion of patients meeting the two conditions is used. The difference in change will use ANCOVA (p9) -why does this ANCOVA model require inclusion of previous thrombo-embolic events and previous ESA dose to test whether the change in Hb differs between groups?
On the whole, the references are up to date and appropriate. However, on pp 4, 5, and 10 (twice), a "manuscript under consideration" is cited. This is not appropriate. If the manuscript is not published, it cannot be cited. If it is published as an abstract, this may be cited as an abstract. A timeline for the actual study would be helpful. Has the study commenced recruiting? When is recruiting anticipated to finish? The SPIRIT checklist is not specifically referred to.
REVIEWER
Bruce Spinowitz New York Presbyterian Queens Weill Cornell School of medicine USA REVIEW RETURNED 20-Nov-2018
GENERAL COMMENTS
1-Trials are too small to adequately assess safety issue with regard to major atherosclerotic CV events. 2-greater detail re: supplemental iron guidelines should be incorporated into the paper-not just referenced.
REVIEWER

Titi Chen
University of Sydney, Australia REVIEW RETURNED 09-Jan-2019
GENERAL COMMENTS
The manuscript entitled "Molidustat for the treatment of renal anaemia in patients with non-dialysis-dependent chronic kidney disease: design and rationale of two phase 3 studies" reports the methodologies of two Japanese trials investigating the efficacy of HIF-PHI Molidustat in non-dialysis CKD patients. The studies are well designed. Together with the other three trials in the MIYABI study, which are published in a separate manuscript, the MIYABI study investigated Molidustat in a broad spectrum of CKD patients. They build on and supplement the existing evidence from the phase 2b trial (DIALOGUE) published recently.
Some minor suggestions: 1. The DIALOGUE study is now published. Could the author please add the reference to the DIALOGUE study? 2. Please clarify the methods used to randomize samples.
VERSION 1 -AUTHOR RESPONSE
Response to reviewer comments
Reviewer comment Response Revision (marked version) Reviewer #1 At times, the text jumps from one study to the other. A better approach may be to structure each section to address the common features of the two studies in the first part of the section, followed by the aspects of each study that are unique in separate paragraphs. Is it planned to report each study separately, or as one report?
The manuscript has been restructured as suggested. It is planned that the results of MIYABI ND-C and MIYABI ND-M will be reported in the same manuscript.
'Study designs, objectives and populations' and 'Treatments' subsections
The objectives are stated generally on pp 5-6 as "efficacy and long-term safety" and the primary outcome(s) should be consistent with this.
The primary objective of both studies is to demonstrate the efficacy of 30-36 weeks of treatment with molidustat. Safety, which is assessed after 52 weeks, is a secondary objective of the studies. This has been clarified in the text.
Line 128-130
On p8, the efficacy variable is the mean Hb during the evaluation period, and its change from baseline. Are these separate for each study? I
The primary efficacy variables are the same for both studies. The primary objective of MIYABI ND-C and MIYABI ND-M is correcting and
Line 194
Line 224 would have thought that the mean Hb level during the evaluation is relevant to MIYABI ND-M, and the change from baseline more important for MIYABI NC-C. maintaining the Hb levels and maintaining the Hb levels, respectively. This has been clarified in the text.
The Screening period is not adequately described. How often will patients be seen during the screening period? Is eligibility based on two measurements of Hb within the stated ranges? If so, how far apart will the measurements be?
Details relating to the screening period are specified in line 150 (MIYABI ND-C) and line 159 (MIYABI ND-M). Further details relating to the measurements of Hb are specified in Table 1 . This has now also been included in the main text: "Hb measurements must be taken at least 2 days apart, the difference between the two measurements must be less than 1.2 g/dL and the last measurements must be taken within 14 days before randomisation". With patients in MIYABI ND-M, will there be a period of time after switching from their pre-study ESA to darbepoetin? There may be a period of instability after switching and it may take time to fine tune the darbepoetin dose. A rationale for doing this, or not doing this, should be provided.
The time period after switching from the pre-study ESAs takes into account the half-life of the ESA. Further details relating to this are specified in Table 1 : "Treated with darbepoetin alfa with biweekly or monthly dose, epoetin beta pegol with monthly dose, or epoetin alfa/beta weekly or biweekly, and having had no more than one dose change during the 8 weeks before randomisation."
No change
It is stated that Ethics approval has been obtained. The name of the Ethics Committee and the application number should be provided.
The MIYABI ND-C study has been approved by the institutional review board of Kyushu University Hospital (application number: 20171211), Nihon University Hospital (application number: 20171130) and a further 60 sites. The MIYABI ND-M study has been approved by the institutional review board of Kyushu University Hospital (application number: 20171211), Nihon University Hospital (application number: 20171130) and 59 additional sites.
Similarly, has the data safety monitoring committee actually been appointed, or is this something planned for the future? Data monitoring committees have been appointed for both studies.
The primary outcomes are discussed in more detail on pp 8-9 and again, it
The primary objective is common to both studies and is assessed in the Line 246 is not clear whether these are the same for both studies, though one has to assume that they are. same manner. This has been clarified in the text: "For both studies, the primary objective will be achieved if two conditions are met". Please clarify whether the mean and 95% CI of the treatment groups must be within 11-13g/dL, or whether this really is each patient's mean and 95% CI.
The mean and 95% CI of the molidustat group must be within 11-13 g/dL to achieve the first condition of the primary objective. This has been clarified in the text.
Line 246-252
Given there are 4 measures during the evaluation period, it is highly likely that the lower and upper bounds of the 95% CI of each patient will cross the boundaries. What is the reason for such a stringent measure of Hb being within target?
For the primary efficacy analysis, the mean of the mean Hb levels per patient must be within the target range, not all of 4 measurements of each patient Hb.
No change
Is the intention to report as the primary outcome the actual mean Hb between groups, or the proportion meeting the primary efficacy criteria? The sample size calculation appears to be based on the former. On p 8 it is stated that "The primary objective will be achieved if two conditions are met". This implies an outcome where the proportion of patients meeting the two conditions is used.
For both studies, the mean Hb levels of the molidustat and darbepoetin alfa treatment arms will be reported. If these results meet two pre-specified criteria then we will conclude that the primary objective has been achieved (ie, the study has demonstrated the efficacy of 30-36 weeks of molidustat treatment for renal anaemia). The sample size of 75 patients per treatment arm in each study was chosen to obtain sufficient data for assessment of the long-term safety of molidustat. This sample size is expected to be sufficient to determine whether the mean Hb level during the evaluation period (weeks 30-36) in the molidustat treatment arm is within the target range and to demonstrate the noninferiority of molidustat to darbepoetin alfa using a noninferiority margin of 1.0 g/dL. These details have been added to the manuscript.
Line 276-279
Line 294-296
The difference in change will use ANCOVA (p9) -why does this ANCOVA model require inclusion of previous thrombo-embolic events and previous ESA dose to test whether the change in Hb differs between groups?
The ANCOVA model requires inclusion of thromboembolic events and previous ESA dose because the randomization will be stratified by previous ESA dose and previous thromboembolic events.
No change
On the whole, the references are up to date and appropriate. However, on pp 4, 5, and 10 (twice), a "manuscript This manuscript has now been published; therefore, the relevant citations have been updated and Reference 22 under consideration" is cited. This is not appropriate. If the manuscript is not published, it cannot be cited. If it is published as an abstract, this may be cited as an abstract.
Macdougall et al, 2019 has been added to the reference list.
A timeline for the actual study would be helpful. Has the study commenced recruiting? When is recruiting anticipated to finish?
Both studies were initiated in December 2017 and have finished recruiting. These details have been added to the manuscript.
Line 134-135
The SPIRIT checklist is not specifically referred to.
The protocols for both studies were written in accordance with SPIRIT guidelines, with the exception of item number 15 (strategies for achieving adequate participant enrolment to reach target sample size) and 31b (authorship eligibility guidelines and any intended use of professional writers).
No change
Reviewer #2 1-Trials are too small to adequately assess safety issue with regard to major atherosclerotic CV events.
We agree with the reviewer and have added the following sentence: "However, it should be noted that this sample size is too small to adequately assess safety with regards to the risk of cardiovascular events."
Line 298-299 2-greater detail re: supplemental iron guidelines should be incorporated into the paper-not just referenced
We agree with the reviewer and have updated the manuscript accordingly. The following sentence has been added: "Iron supplementation will be orally administered to reach a target serum ferritin level of at least 100 ng/mL or transferrin saturation of at least 20%."
Line 219-221
Reviewer #3 1. The DIALOGUE study is now published. Could the author please add the reference to the DIALOGUE study?
The relevant citations have been updated accordingly and Macdougall et al, 2019 has been added to the reference list.
Reference 22 2. Please clarify the methods used to randomize samples
The following sentence has been added: "Allocation to treatment arms will be achieved using an interactive voice/web response system (IxRS) at the baseline visit". 
